SPRINT and the Kidney: What Have We Learned?
- 201 Downloads
Purpose of Review
To review the impact of the Systolic Blood Pressure Interventional Trial (SPRINT) on renal function and chronic kidney disease.
Hypertension is a risk factor for cardiovascular and kidney outcomes in patients with chronic kidney disease (CKD). The benefits of intensive blood pressure lowering in the CKD population in previous studies are unclear. The SPRINT compared standard (< 140 mmHg) and intensive (< 120 mmHg) blood pressure management in nondiabetic patients with high risk of cardiovascular disease. In the subgroup of patients with CKD, the most important finding was that intensive blood pressure lowering is associated with lower risk of cardiovascular disease and mortality. Other than lower levels of albuminuria, there was no benefit on clinical kidney outcomes with the intensive treatment group. The risk of incident CKD and episodes of acute kidney injury was higher in patients in the intensive treatment group, though most patients with acute kidney injury recovered kidney function.
While the benefit of intensive blood pressure lowering on cardiovascular events and mortality with intensive blood pressure lowering is clear in patients with CKD, longer term follow-up may be needed to fully understand the effect on kidney function.
KeywordsBlood pressure monitoring Chronic kidney disease Acute kidney injury SPRINT
This study was supported by a grant from the National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interest
Dr. Rahman reports grants from NIH, during the conduct of the study; Dr. Wells declares no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 5.James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507–20.CrossRefGoogle Scholar
- 7.• A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. This trial highlighted the importance of reduction in blood pressure goals to improve cardiovascular outcomes. Google Scholar
- 8.Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials (London, England). 2014;11(5):532–46.CrossRefGoogle Scholar
- 9.• Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol : JASN. 2017;28(9):2812–23. This paper focuses on the CKD population of SPRINT and the improvement in cardiovascular outcomes within both treatment arms and the lack of difference in main kidney outcomes between treatment arms. CrossRefGoogle Scholar
- 10.• Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med. 2017;167(6):375–83. This paper focuses on the non-CKD population of SPRINT and the impact of blood pressure lowering on renal outcomes. CrossRefGoogle Scholar
- 12.• SRocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, et al. Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2017;71(3):352–61. This paper summarizes the effect of blood pressure reduction with increased acute kidney injuries. Google Scholar